Cargando…
Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients
The objective of this research was to optimize the tasted-masked microparticles for orally disintegrating tablets containing donepezil hydrochloride using quality risk assessment and design of experiment approaches. The double emulsion solvent evaporation technique using aminoalkyl methacrylate copo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309182/ https://www.ncbi.nlm.nih.gov/pubmed/34371737 http://dx.doi.org/10.3390/pharmaceutics13071046 |
_version_ | 1783728462338457600 |
---|---|
author | Sutthapitaksakul, Lalinthip Thanawuth, Kasitpong Dass, Crispin R. Sriamornsak, Pornsak |
author_facet | Sutthapitaksakul, Lalinthip Thanawuth, Kasitpong Dass, Crispin R. Sriamornsak, Pornsak |
author_sort | Sutthapitaksakul, Lalinthip |
collection | PubMed |
description | The objective of this research was to optimize the tasted-masked microparticles for orally disintegrating tablets containing donepezil hydrochloride using quality risk assessment and design of experiment approaches. The double emulsion solvent evaporation technique using aminoalkyl methacrylate copolymer (AMC) was used to prepare taste-masked microparticles. Factors affecting the quality of the taste-masked microparticles were analyzed using an Ishikawa diagram. A risk-ranking approach was used to rank the formulation and process risks. Furthermore, the effect of AMC quantity, stirring time, and volume of outer water phase on various responses, such as particle size, the amount of drug dissolved at 5 min (Q(5)) in simulated saliva fluid, and mean dissolution time (MDT) in simulated gastric fluid, was investigated using the Box-Behnken design. The optimized microparticles were then used to prepare orally disintegrating tablets (ODTs) and evaluated by in vitro and in vivo testing. The results demonstrated that particle size was influenced by the AMC amount and stirring time. Q(5) was significantly affected by the amount of AMC and the volume of the outer water phase. On the other hand, these two factors had a positive effect on MDT. The optimized microparticles had a particle size of 174.45 ± 18.19 µm, Q(5) of 5.04%, and MDT of 5.97 min. The ODTs with taste-masked microparticles showed acceptable in vitro dissolution with an MDT of 5 min. According to the results of a panel of six human volunteers, they greatly improved palatability. |
format | Online Article Text |
id | pubmed-8309182 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83091822021-07-25 Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients Sutthapitaksakul, Lalinthip Thanawuth, Kasitpong Dass, Crispin R. Sriamornsak, Pornsak Pharmaceutics Article The objective of this research was to optimize the tasted-masked microparticles for orally disintegrating tablets containing donepezil hydrochloride using quality risk assessment and design of experiment approaches. The double emulsion solvent evaporation technique using aminoalkyl methacrylate copolymer (AMC) was used to prepare taste-masked microparticles. Factors affecting the quality of the taste-masked microparticles were analyzed using an Ishikawa diagram. A risk-ranking approach was used to rank the formulation and process risks. Furthermore, the effect of AMC quantity, stirring time, and volume of outer water phase on various responses, such as particle size, the amount of drug dissolved at 5 min (Q(5)) in simulated saliva fluid, and mean dissolution time (MDT) in simulated gastric fluid, was investigated using the Box-Behnken design. The optimized microparticles were then used to prepare orally disintegrating tablets (ODTs) and evaluated by in vitro and in vivo testing. The results demonstrated that particle size was influenced by the AMC amount and stirring time. Q(5) was significantly affected by the amount of AMC and the volume of the outer water phase. On the other hand, these two factors had a positive effect on MDT. The optimized microparticles had a particle size of 174.45 ± 18.19 µm, Q(5) of 5.04%, and MDT of 5.97 min. The ODTs with taste-masked microparticles showed acceptable in vitro dissolution with an MDT of 5 min. According to the results of a panel of six human volunteers, they greatly improved palatability. MDPI 2021-07-09 /pmc/articles/PMC8309182/ /pubmed/34371737 http://dx.doi.org/10.3390/pharmaceutics13071046 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sutthapitaksakul, Lalinthip Thanawuth, Kasitpong Dass, Crispin R. Sriamornsak, Pornsak Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients |
title | Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients |
title_full | Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients |
title_fullStr | Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients |
title_full_unstemmed | Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients |
title_short | Optimized Taste-Masked Microparticles for Orally Disintegrating Tablets as a Promising Dosage Form for Alzheimer’s Disease Patients |
title_sort | optimized taste-masked microparticles for orally disintegrating tablets as a promising dosage form for alzheimer’s disease patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309182/ https://www.ncbi.nlm.nih.gov/pubmed/34371737 http://dx.doi.org/10.3390/pharmaceutics13071046 |
work_keys_str_mv | AT sutthapitaksakullalinthip optimizedtastemaskedmicroparticlesfororallydisintegratingtabletsasapromisingdosageformforalzheimersdiseasepatients AT thanawuthkasitpong optimizedtastemaskedmicroparticlesfororallydisintegratingtabletsasapromisingdosageformforalzheimersdiseasepatients AT dasscrispinr optimizedtastemaskedmicroparticlesfororallydisintegratingtabletsasapromisingdosageformforalzheimersdiseasepatients AT sriamornsakpornsak optimizedtastemaskedmicroparticlesfororallydisintegratingtabletsasapromisingdosageformforalzheimersdiseasepatients |